KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTC BB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, announced that a patent application has been published for U.S. and international patents covering the combination of local and systemic immunomodulative therapies for cancer treatment.
The patent, entitled "Combination of Local and Systemic Immunomodulative Therapies for Enhanced Treatment of Cancer," covers a method of treatment of cancer that comprises administering a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. The systemic immunomodulatory anticancer agent comprises anti-CTLA-4 antibodies including ipilimumab and tremelimumab.
Dr. Craig Dees, PhD, CEO of Provectus said, "We are pleased that this joint patent application has been published as we continue to develop our intellectual property claims. We are excited about the potential of combining PV-10, our intralesional chemoablative therapy, with other anticancer agents as appropriate, and expanding its use in broader applications."
This patent can be accessed at the following link: http://patentscope.wipo.int/search/en/detail.jsf?docId=WO2012122444
About Provectus Pharmaceuticals, Inc.
Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver. The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. Information about these and the Company's other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.
Provectus Pharmaceuticals, Inc. Peter R. Culpepper, CFO, COO 866-594-5999 #30 or Porter, LeVay & Rose, Inc. Marlon Nurse, DM, SVP - Investor Relations Bill Gordon, SVP - Media Relations 212-564-4700
(c) 2002-2015 Provectus Biopharmaceuticals, Inc.
All rights reserved.
Artwork designed by Tracy E. Miller.